Connect Biopharma Holdings Limited (CNTB) quarterly income statement — complete revenue, gross profit & net income history
Connect Biopharma Holdings Limited (CNTB) annual income statement — 7-year revenue, gross profit & net income history
| Metric | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 | Q4'20 | Q4'19 | Q2'19 |
|---|
| Sales/Revenue | 2.94M | 0 | 48K | 698K | 24.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 6018.75% | -100% | -99.8% | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 506.13K | 527.3K | 0 | 412.05K | 221.39K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.94M | 0 | 48K | 698K | 24.12M | 0 | -506.13K | -527.3K | 0 | -412.05K | -221.39K | 0 | 0 | 0 |
| Gross Margin % | 100% | - | 100% | 100% | 100% | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 6018.75% | -100% | -99.8% | - | 4864.81% | 100% | - | -27.97% | 100% | - | - | - | - | - |
| Operating Expenses | 40.15M | 15.53M | 13.47M | 10.32M | 10.47M | 36.95M | 34.34M | 53.76M | 59.97M | 57.85M | 40.87M | 107.47K | 8.22M | 8.22M |
| OpEx % of Revenue | 1366.97% | - | 28066.67% | 1478.08% | 43.42% | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.1M | 4.24M | 4.7M | 4.08M | 5.12M | 7.96M | 7.61M | 9.16M | 10.72M | 11.17M | 7.19M | 6.22K | 704.57K | 704.57K |
| SG&A % of Revenue | 139.56% | - | 9789.58% | 584.67% | 21.24% | - | - | - | - | - | - | - | - | - |
| Research & Development | 16.27M | 11.28M | 8.77M | 6.24M | 5.35M | 26.36M | 26.73M | 44.6M | 50.66M | 46.68M | 33.67M | 14.08K | 7.72M | 7.72M |
| R&D % of Revenue | 554.07% | - | 18277.08% | 893.41% | 22.18% | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | -1000K | 0 | 0 | 0 | -205.72K | -205.72K |
| Operating Income | -37.21M | -15.53M | -13.42M | -9.62M | 13.65M | -36.95M | -34.84M | -54.28M | -59.97M | -58.26M | -41.09M | -19.65K | -8M | -8M |
| Operating Margin % | -1266.97% | - | -27966.67% | -1378.08% | 56.58% | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -177.2% | -61.41% | -198.37% | 73.97% | 139.16% | 31.93% | 41.89% | 6.83% | -45.94% | - | - | 99.75% | - | - |
| EBITDA | -36.89M | -15.35M | -13.25M | -9.44M | 13.97M | -36.6M | -34.34M | -53.76M | -59.46M | -57.85M | -40.87M | -19.53K | -7.94M | -7.94M |
| EBITDA Margin % | -1255.91% | - | -27610.42% | -1351.72% | 57.94% | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -178.32% | -62.64% | -194.85% | 74.22% | 140.69% | 31.91% | 42.25% | 7.08% | -45.5% | - | - | 99.75% | - | - |
| D&A (Non-Cash Add-back) | 325K | 181K | 171K | 184K | 326K | 350K | 506.13K | 527.3K | 502.72K | 412.05K | 221.39K | 118 | 57.3K | 57.3K |
| EBIT | -37.21M | -15.08M | -12.84M | -8.8M | 14.9M | -35.69M | -30.51M | -56.48M | -61.35M | -56.39M | -20.58M | -19.65M | -12.2M | -12.2M |
| Net Interest Income | 313K | 1.65M | 619K | 4.03M | 802K | -2.48M | 2.48M | 1.28M | 262.38K | 55 | 23 | 375 | 73.48K | 73.48K |
| Interest Income | 313K | 1.65M | 619K | 4.03M | 822K | -2.49M | 2.49M | 1.29M | 271.1K | 55 | 23 | 375 | 77.33K | 77.33K |
| Interest Expense | 0 | 0 | 0 | 0 | 20K | -10.39K | 10.39K | 12.32K | 8.72K | 0 | 0 | 0 | 3.85K | 3.85K |
| Other Income/Expense | 637K | 444K | 580K | 819K | 1.23M | 5.37M | 4.33M | -2.21M | 184.47K | 1.87M | -104.62M | 20.61M | -4.21M | -4.21M |
| Pretax Income | -36.57M | -15.08M | -12.84M | -8.8M | 14.88M | -31.58M | -30.52M | -56.49M | -59.78M | -56.39M | -145.71M | -107.85K | -12.23M | -12.23M |
| Pretax Margin % | -1245.28% | - | -26758.33% | -1260.74% | 61.69% | - | - | - | - | - | - | - | - | - |
| Income Tax | 108K | 27K | 55K | 106K | 30K | 56K | 64.78K | 186.17K | 110K | 263.87K | 0 | 0 | -221.24K | -221.24K |
| Effective Tax Rate % | -0.3% | -0.18% | -0.43% | -1.2% | 0.2% | -0.18% | -0.21% | -0.33% | -0.18% | -0.47% | 0% | 0% | 1.81% | 1.81% |
| Net Income | -36.68M | -15.11M | -12.9M | -8.91M | 14.85M | -31.63M | -30.58M | -56.68M | -59.89M | -56.65M | -145.71M | -107.85K | -12.01M | -12.01M |
| Net Margin % | -1248.96% | - | -26872.92% | -1275.93% | 61.56% | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -184.38% | -69.65% | -186.88% | 71.84% | 148.55% | 44.19% | 48.94% | -0.05% | 58.9% | -52429.29% | - | 99.1% | - | - |
| Net Income (Continuing) | -36.68M | -15.11M | -12.9M | -8.91M | 14.85M | -31.63M | -30.58M | -56.68M | -59.89M | -56.65M | -145.71M | -107.85M | -12.2M | -12.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.61 | -0.27 | -0.23 | -0.42 | 0.14 | -0.52 | -0.56 | -1.03 | -13.47 | -1.05 | -3.10 | -0.00 | -1.51 | -1.51 |
| EPS Growth % | -165.22% | 35.71% | -264.29% | 19.23% | 125% | 49.51% | 95.84% | 1.9% | -334.52% | - | - | 99.87% | - | - |
| EPS (Basic) | -0.61 | -0.27 | -0.23 | -0.42 | 0.14 | -0.52 | -0.56 | -1.03 | -13.47 | -1.05 | -3.10 | -0.00 | -1.51 | -1.51 |
| Diluted Shares Outstanding | 62.88M | 55.66M | 55.5M | 55.19M | 55.55M | 55.07M | 55.05M | 55.02M | 55.02M | 53.74M | 46.94M | 54.88M | 55.82M | 55.82M |
| Basic Shares Outstanding | 62.88M | 55.66M | 55.5M | 55.19M | 55.14M | 55.07M | 55.05M | 55.02M | 55.02M | 53.74M | 46.94M | 54.88M | 55.82M | 55.82M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |